Literature DB >> 33800247

Schemes for Drug-Induced Treatment of Osteonecrosis of Jaws with Particular Emphasis on the Influence of Vitamin D on Therapeutic Effects.

Filip Michalak1, Sylwia Hnitecka2, Marzena Dominiak1, Kinga Grzech-Leśniak1,3.   

Abstract

Drugs that inhibit bone resorption are prescribed most often by orthopedists, hematologists, or oncologists. Dental practice rarely draws attention to their importance and the effects they carry. The problem concerns mainly older people owing to oncological problems or postmenopausal consequences, but everyone can be at risk. Carefully conducted interviews and analysis of history and disease should always be performed before any action is taken by patients taking this type of medicine. Further action should consider possible complications and, above all, the risk of their occurrence. In this article, the most important issues related to the treatment of drug-induced osteonecrosis of the jaws (ONJ) are raised, including medication-related osteonecrosis of the jaw (MRONJ); conservative treatment, including the use of laser; and the impact of vitamin D supplementation on the overall treatment, prognosis, and prevention before complication, which is osteonecrosis of the jaw in the course of treatment with bisphosphonates and other drugs predisposing to MRONJ, such as denosumab and angiogenesis inhibitors. The degree of osteonecrosis is also critical, as it is possible to avoid surgical procedures for only conservative methods that sometimes bring good results. Surgical treatment of advanced stages is complicated and carries a high risk of error and complications. MRONJ is a disease that is easy to avoid, but it is difficult to treat and treatment sometimes leads only to a partial remission of the disease, not a complete cure.

Entities:  

Keywords:  MRONJ; bisphosphonates; laser therapy; osteonecrosis; vitamin D

Year:  2021        PMID: 33800247      PMCID: PMC7999491          DOI: 10.3390/pharmaceutics13030354

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  66 in total

1.  Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.

Authors:  Salvatore L Ruggiero; John Fantasia; Eric Carlson
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2006-07-31

Review 2.  Making Use of Lasers in Periodontal Treatment: A New Gold Standard?

Authors:  Kinga Grzech-Leśniak
Journal:  Photomed Laser Surg       Date:  2017-06-16       Impact factor: 2.796

3.  Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment?

Authors:  G Favia; A Tempesta; L Limongelli; V Crincoli; E Maiorano
Journal:  Oral Dis       Date:  2018-03       Impact factor: 3.511

Review 4.  Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone.

Authors:  A M Parfitt
Journal:  J Cell Biochem       Date:  1994-07       Impact factor: 4.429

5.  Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women.

Authors:  J C Koster; W H Hackeng; H Mulder
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

6.  Osteonecrosis of the jaws induced by anti-RANK ligand therapy.

Authors:  K H Taylor; L S Middlefell; K D Mizen
Journal:  Br J Oral Maxillofac Surg       Date:  2010-04       Impact factor: 1.651

7.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

8.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

9.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

Authors:  Salvatore L Ruggiero; Bhoomi Mehrotra; Tracey J Rosenberg; Stephen L Engroff
Journal:  J Oral Maxillofac Surg       Date:  2004-05       Impact factor: 1.895

Review 10.  Medication-related osteonecrosis of the jaw: Clinical and practical guidelines.

Authors:  Daniele Rosella; Piero Papi; Rita Giardino; Emauele Cicalini; Luca Piccoli; Giorgio Pompa
Journal:  J Int Soc Prev Community Dent       Date:  2016 Mar-Apr
View more
  1 in total

1.  Efficacy of fibrin-rich platelets and leukocytes (L-PRF) in tissue repair in surgical oral procedures in patients using zoledronic acid-case-control study.

Authors:  Guilherme Klein Parise; Brenda Nazareth Costa; Miriã Lima Nogueira; Laurindo Moacir Sassi; Juliana Lucena Schussel
Journal:  Oral Maxillofac Surg       Date:  2022-06-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.